PRCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Procept BioRobotics Corp (PRCT) does not present a compelling buy opportunity for a beginner, long-term investor with $50,000-$100,000 available. The technical indicators are bearish, options sentiment is neutral to slightly positive, and analysts have recently downgraded the stock due to competitive pressures and uncertainty in inventory dynamics. Additionally, there are no strong positive catalysts or recent financial data to support a buy decision at this time.
The technical indicators for PRCT are bearish. The MACD is negatively expanding below zero (-0.828), the RSI is neutral at 25.364, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 21.852, with resistance levels at 28.781 and 30.922.
Insider buying has increased significantly by 1235.17% over the last month, indicating potential confidence from company insiders.
Hedge funds are selling, with a 465.92% increase in selling activity over the last quarter. Analysts have downgraded the stock due to competitive pressures from prostate artery embolization and uncertainty in inventory dynamics. No recent news or financial data is available to provide additional support for the stock.
No financial data available for analysis. The latest quarter's performance could not be assessed.
Analysts have mixed views. Leerink downgraded the stock to Market Perform with a price target of $29, citing competitive pressures and forecasting uncertainty. Piper Sandler raised the price target to $35 from $28 after strong Q1 results but reiterated an Overweight rating. Baird raised the price target to $28 but maintained a Neutral rating.
